Eye Meds Now

 Quick Ophthalmic Drug Search

231 items found
SOCHLOR (sodium chloride (5%) ophthalmic ointment; ophthalmic solution)
Over the Counter
Topical
Ointment
Ophthalmic Solution
Hyperosmotic Medications
Indications/Usage:

Used for the temporary relief of corneal edema as an eye lubricant.


Typical Dosing:  

Corneal edema:

  • Ophthalmic ointment:
    • Apply a small amount (¼ inch) to the inside of the affected eye(s) every 3 – 4 hours, or as needed.
  • Ophthalmic solution:
    • Instill 1 – 2 drops in the affected eye(s) every 3 – 4 hours, or as needed.

Recurrent corneal erosion, chronic:

  • Ophthalmic ointment:
    • Pull down the lower lid of affected eye and apply a small amount (¼ inch) of ointment to the inside of eyelid every night at bedtime.
    • Continue treatment for 3 – 6 months.
  • Ophthalmic solution:
    • Instill 1 – 2 drops in the affected eye(s) 4 times daily.
    • Continue treatment for 3 – 6 months.
Recurrent corneal erosion typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

 


How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes (generic only)
  • Ophthalmic solution:
    • 15 mL bottles

Preservatives:  

None listed in package insert (ophthalmic ointment); methylparaben, polyparaben (ophthalmic solution)


Storage:  
  • Store at room temperature 59° – 86°F (15° – 30°C).
  • Keep from freezing.
  • Keep tightly closed.
  • See crimp of tube or box for ointment lot number and expiration date.


SODIUM CHLORIDE (sodium chloride (5%) ophthalmic ointment; ophthalmic solution)
Over the Counter
Topical
Ointment
Ophthalmic Solution
Hyperosmotic Medications
Indications/Usage:

Indicated for temporary relief of corneal edema.


Typical Dosing:  

Corneal edema:

  • Ophthalmic ointment:
    • Apply small amount (¼ inch) to the inside of affected eye(s) every 3  4 hours, or as needed.
  • Ophthalmic solution:
    • Instill 1   2 drops in the affected eye(s) as needed.

Recurrent corneal erosion, chronic:

  • Ophthalmic ointment:
    • Pull down the lower lid of affected eye and apply a small amount (¼ inch) of ointment to the inside of eyelid every night at bedtime.
    • Continue treatment for 3 – 6 months.
  • Ophthalmic solution:
    • Instill 1 – 2 drops in the affected eye(s) 4 times daily.
    • Continue treatment for 3 – 6 months.
Recurrent corneal erosion typical dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

 


How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic solution:
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Store away from heat.
  • Protect from freezing.
  • Keep tightly closed.
  • See crimp on ointment tube for control number and expiration date.


TEPEZZA (teprotumumab-trbw (500 mg) powder for reconstitution and intravenous injection)
Prescription
Injectable
IV
Other Medications
Indications/Usage:

Indicated for the treatment of thyroid eye disease.


Typical Dosing:  

Thyroid eye disease, recommended:

  • Intravenous infusion of 10 mg/kg for the initial dose followed by an intravenous infusion of 20 mg/kg every 3 weeks for 7 additional infusions.
  • Dilute solution as described in package insert or in Notes below.
  • Administration:
    • Administer the diluted solution intravenously over 90 minutes for the first 2 infusions. If well tolerated, the minimum time for subsequent infusions can be reduced to 60 minutes. If not well tolerated, the minimum time for subsequent infusions should remain at 90 minutes.
    • Do not administer as an intravenous push or bolus. TEPEZZA should not be infused concomitantly with other agents.
  • Additional information for Reconstitution and Preparation is in Notes below.

How Supplied:  
  • 500 mg single dose vials
    • white to off-white lyophilized powder for reconstitution and dilution

Preservatives:  

None listed in package insert.


Storage:  
  • Refrigerate at 36° – 46°F (2° – 8°C).
  • Store in original carton until time of use to protect from light.
  • Do not freeze.


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

TETRACAINE (tetracaine hydrochloride (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Anesthetic Medications
Indications/Usage:

Indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.


Typical Dosing:  

 Rapid and short-acting topical ophthalmic anesthetic:

  • Topical administration:
    • 1 drop topically in the eye as needed. Discard unused portion.
  • Sterile field administration:
    • Open package using standard aseptic technique. The DROP-TAINER® dispenser may then be allowed to fall upon a sterile surface. The entire outer surface of the DROP-TAINER® dispenser and its contents are sterile.

How Supplied:  
  • 1 mL bottles
  • 4 mL bottles
  • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36° – 77°F (2° – 25°C).
  • Protect from light.
  • Do not use if solution contains crystals, is cloudy or is discolored.


TIMOPTIC (timolol maleate (0.25%; 0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.

TIMOPTIC IN OCUDOSE ONLY: May be used when a patient is sensitive to the preservative in TIMOPTIC® (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma:

  • Ophthalmic solution:
    • Available in concentrations of 0.25% and 0.5%:
      • The usual starting dose is 1 drop of 0.25% in the affected eye(s) twice a day.
      • If the clinical response is not adequate, the dosage may be changed to 1 drop of 0.5% solution in the affected eye(s) twice a day.
    • Since in some patients the pressure-lowering response to TIMOPTIC may require a few weeks to stabilize, evaluation should include a determination of IOP after approximately 4 weeks of treatment with TIMOPTIC.
    • If the IOP is maintained at satisfactory levels, the dosage schedule may be changed to 1 drop once a day in the affected eye(s).
    • Because of diurnal variations in IOP, satisfactory response to the once-a-day dose is best determined by measuring the IOP at different times during the day.
    • Dosages above 1 drop of 0.5% TIMOPTIC twice a day generally have not been shown to produce further reduction in intraocular pressure.
    • If the patient's IOP is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering IOP can be instituted.
    • The concomitant use of two topical beta-adrenergic blocking agents is not recommended [See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert].
  • Ophthalmic solution in OCUDOSE:
    • Available in concentrations of 0.25% and 0.5%:
      • The usual starting dose is 1 drop of 0.25% in the affected eye(s) administered twice a day. Apply enough gentle pressure on the individual container to obtain a single drop of solution.
      • If the clinical response is not adequate, the dosage may be changed to 1 drop of 0.5% solution in the affected eye(s) administered twice a day.
    • Since in some patients the pressure-lowering response to Preservative-free TIMOPTIC in OCUDOSE may require a few weeks to stabilize, evaluation should include a determination of IOP after approximately 4 weeks of treatment with Preservative-free TIMOPTIC in OCUDOSE.
    • If the IOP is maintained at satisfactory levels, the dosage schedule may be changed to 1 drop once a day in the affected eye(s).
    • Because of diurnal variations in IOP, satisfactory response to the once-a-day dose is best determined by measuring the IOP at different times during the day.
    • Dosages above 1 drop of 0.5% TIMOPTIC (timolol maleate ophthalmic solution) twice a day generally have not been shown to produce further reduction in IOP.
    • If the patient's IOP is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering IOP can be instituted taking into consideration that the preparation(s) used concomitantly may contain one or more preservatives.
    • The concomitant use of 2 topical beta-adrenergic blocking agents is not recommended (See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert).
  • Additional information for keeping OCUDOSE solution sterile is in Notes below.

How Supplied:  
  • Ophthalmic solution:
    • 0.25% ophthalmic solution
      • 5 mL bottles
      • 10 mL bottles (generic only)
      • 15 mL bottles (generic only)
    • 0.5% ophthalmic solution
      • 2.5 mL bottles (generic only)
      • 5 mL bottles
      • 10 mL bottles
      • 15 mL bottles (generic only)
  • Ophthalmic solution in OCUDOSE (Preservative free):
    • 0.25% ophthalmic solution
      • 0.3 mL in 60 unit dose containers
    • 0.5% ophthalmic solution
      • 0.3 mL in 60 unit dose containers

Preservatives:  

benzalkonium chloride (ophthalmic solution); none listed in package insert (OCUDOSE).


Storage:  
  • Store at room temperature 59° – 77°F (15° – 25°C).
  • Protect from freezing.
  • Protect from light.
  • Ophthalmic solution in OCUDOSE: Because evaporation can occur through the unprotected polyethylene unit dose container and prolonged exposure to direct light can modify the product, the unit dose container should be kept in the protective foil overwrap and used within 1 month after the foil package has been opened.


Assistance: Payment Assistance

TIMOPTIC-XE (timolol maleate (0.25%; 0.5%) gel forming ophthalmic solution)
Prescription
Topical
Gel
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma:

  • Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once.
  • Other topically applied ophthalmic medications should be administered at least 10 minutes before TIMOPTIC-XE [See PRECAUTIONS, Information for Patients and accompanying INSTRUCTIONS FOR USE in package insert].
  • Available in concentrations of 0.25% and 0.5% (See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert):
    • The dose is 1 drop of TIMOPTIC-XE (either 0.25% or 0.5%) in the affected eye(s) once a day.
  • Because in some patients the pressure-lowering response to TIMOPTIC-XE may require a few weeks to stabilize, evaluation should include a determination of IOP after approximately 4 weeks of treatment with TIMOPTIC-XE.
  • Dosages higher than 1 drop of 0.5% TIMOPTIC-XE once a day have not been studied. If the patient's IOP is still not at a satisfactory level on this regimen, concomitant therapy can be considered.
  • The concomitant use of 2 topical beta-adrenergic blocking agents is not recommended [See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert].
  • When patients have been switched from therapy with TIMOPTIC administered 2 times daily to TIMOPTIC-XE administered 1 time daily, the ocular hypotensive effect has remained consistent.

How Supplied:  
  • 0.25% ophthalmic solution
    • 5 mL bottles
  • 0.5% ophthalmic solutuion
    • 5 mL bottles

Preservatives:  

benzododecinium bromide


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Avoid freezing.
  • Protect from light.


TOBRADEX (tobramycin (0.3%) – dexamethasone (0.1%) ophthalmic ointment; ophthalmic suspension)
Prescription
Topical
Ointment
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. 

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.

They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens:

Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammatory ocular conditions:

  • Ophthalmic ointment:
    • Apply a small amount (approximately ½ inch ribbon) into the conjunctival sac(s) up to 3 – 4 times daily. 
    • How to apply:
      • Tilt your head back.
      • Place a finger on your cheek just under your eye and gently pull down until a "V” pocket is formed between your eyeball and your lower lid.
      • Place a small amount (about ½ inch) in the "V" pocket. Do not let the tip of the tube touch your eye.
      • Look downward before closing your eye.
    • Not more than 8 g should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.
  • Ophthalmic suspension:
    • Instill 1 or 2 drops into the conjunctival sac(s) every 4 – 6 hours. 
    • During the initial 24 – 48 hours, the dosage may be increased to 1 or 2 drops every 2 hours.
    • Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.
    • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic suspension:
    • 2.5 mL bottles
    • 5 mL bottles
    • 10 mL bottles

Preservatives:  

chlorobutanol (ophthalmic ointment);  benzalkonium chloride (ophthalmic suspension)


Storage:  
  • Ophthalmic ointment:
    • Store at 36° – 77°F (2° – 25°C).
    • After opening, TOBRADEX® ointment can be used until the expiration date on the tube.
  • Ophthalmic suspension:
    • Store suspension at 46° – 80°F (8° – 27°C).
    • Store suspension upright.
    • Shake suspension well before using.
    • After opening, TOBRADEX® suspension can be used until the expiration date on the tube.


TOBRADEX ST (tobramycin (0.3%) – dexamethasone (0.5%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.  They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant isolates. Streptococci, including some Group A and other beta-hemolytic species, some nonhemolytic Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris isolates, Haemophilus influenzae, H. aegyptius, Moraxella lacunata, Acinetobacter and some Neisseria species.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Steroid-responsive ocular infections and inflammatory conditions, recommended:

  • Instill 1 drop into the conjunctival sac(s) every 4 – 6 hours. During the initial 24 – 48 hours, dosage may be increased to 1 drop every 2 hours. 
  • Frequency should be decreased gradually as warranted by improvement in clinical signs, but care should be taken not to discontinue therapy prematurely.
  • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in WARNINGS AND PRECAUTIONS (5) in package insert.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).
  • Protect from light.


TOBRAMYCIN (tobramycin (0.3%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany use.

This medication has a broad FDA approval for "external infections of the eye and its adnexa." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "external infections of the eye and its adnexa." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

External infections of the eye and its adnexa caused by susceptible bacteria:

►Mild to moderate disease:

  • Instill 1 – 2 drops into the affected eye(s) every 4 hours.

 ►Severe infections:

  • Instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

►Recurrent corneal erosion:

  • Follow normal dosing patterns; typically 2 – 3 times/day.

How Supplied:  
  • 5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36° – 77°F (2°– 25°C).
  • After opening, solution can be used until the expiration date on the bottle.


TOBRAMYCIN/DEXAMETHASONE (tobramycin (0.3%) – dexamethasone (0.1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. 

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.

They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens:

Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammatory ocular conditions:

  • Instill 1 or 2 drops into the conjunctival sac(s) every 4 – 6 hours. 
  • During the initial 24 – 48 hours, the dosage may be increased to 1 or 2 drops every 2 hours.
  • Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.
  • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store suspension at 46° – 80°F (8° – 27°C).
  • Store suspension upright.
  • Shake suspension well before using.
  • After opening, tobramycin/dexamethasone ophthalmic suspension can be used until the expiration date on the tube.


TOBREX (tobramycin (0.3%) ophthalmic ointment; ophthalmic solution)
Prescription
Topical
Ointment
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany use.

This medication has a broad FDA approval for "external infections of the eye and its adnexa." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "external infections of the eye and its adnexa." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

External infections of the eye and its adnexa caused by susceptible bacteria:

►Mild to moderate disease:

  • Ophthalmic ointment:
    • Instill a ½ inch ribbon into the affected eye(s) 2 – 3 times per day.
  • Ophthalmic solution:
    • Instill 1 – 2 drops into the affected eye(s) every 4 hours.

 ►Severe infections:

  • Ophthalmic ointment:
    • Instill a ½ inch ribbon into the affected eye(s) every 3 – 4 hours until improvement, following which treatment should be reduced prior to discontinuation.
  • Ophthalmic solution:
    • Instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

►Recurrent corneal erosion:

  • Follow normal dosing patterns; typically 2 – 3 times/day.

Additional information for applying ointment is included in Notes below.


How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic solution:
    • 5 mL bottles

Preservatives:  

chlorobutanol (ophthalmic ointment); benzalkonium chloride (ophthalmic solution)


Storage:  
  • Ophthalmic ointment:
    • Store at 46°– 80°F (8°– 27°C).
    • After opening, ointment can be used until the expiration date on the tube.
  • Ophthalmic solution:
    • Store at 36° – 77°F (2°– 25°C).
    • After opening, solution can be used until the expiration date on the bottle.


TRAVATAN Z (travoprost (0.004%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, recommended:

  • Instill 1 drop in the affected eye(s) once daily in the evening.
  • Should not be administered more than 1 time daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect.
  • Reduction of the IOP starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

sofZia® (boric acid, propylene glycol, sorbitol, zinc chloride)


Storage:  
  • Store at 36° – 77°F (2° – 25°C)
  • After opening, can be used until the expiration date on the bottle.


Assistance: Payment Assistance

TRAVOPROST (travoprost (0.004%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • Instill 1 drop in the affected eye(s) once daily in the evening.
  • Should not be administered more than 1 time daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect.
  • Reduction of IOP starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36º – 77ºF (2º – 25ºC).


TRIAMCINOLONE (triamcinolone acetonide (0.025%; 0.1%; 0.5%) topical cream)
Prescription
Topical
Cream
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

This medication has a broad FDA approval for "inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Eyelid dermatitis (allergic, eczematous, or xeroderma):

  • Apply to the affected area as a thin film 2 – 4 times daily depending on the severity of the condition.
  • Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.

How Supplied:  
  • 0.025% topical cream:
    • 15 g tubes
    • 80 g tubes
    • 454 g tubes
  • 0.1% topical cream:
    • 15 g tubes
    • 30 g tubes
    • 80 g tubes
    • 454 g tubes
  • 0.5% topical cream:
    • 15 g tubes

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


TRIESENCE (triamcinolone acetonide (4%) ophthalmic injection suspension)
Prescription
Injectable
Intravitreal
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Also indicated for visualization during vitrectomy.


Typical Dosing:  

►Treatment of ophthalmic diseases, recommended:

  • Initial dose of 4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment.

►Visualization during vitrectomy:

  • Initial dose of 1 – 4 mg (25 – 100 microliters of 40 mg/mL suspension) administered intravitreally.

►Additional information for Administration is in Notes below.


How Supplied:  
  • 1 mL single-use vials

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 39° – 77°F (4° – 25°C).
  • Do not freeze.
  • Protect from light by storing in carton.


TRIFLURIDINE (trifluridine (1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antivirals
Indications/Usage:

Indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2.


Typical Dosing:  

Primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2:

  • Instill 1 drop onto the cornea of the affected eye every 2 hours while awake for a maximum daily dosage of 9 drops until the corneal ulcer has completely re-epithelialized.
  • Following re-epithelialization, treatment for an additional 7 days of 1 drop every 4 hours while awake for a minimum daily dosage of 5 drops is recommended.
  • If there are no signs of improvement after 7 days of therapy or complete re-epithelialization has not occurred after 14 days of therapy, other forms of therapy should be considered. Continuous administration of trifluridine for periods exceeding 21 days should be avoided because of potential ocular toxicity.

How Supplied:  
  • 7.5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store under refrigeration 36° – 46°F (2° – 8°C).


TRIMETHOPRIM/POLYMYXIN B (trimethoprim sulfate (0.1%) – polymyxin B sulfate (10,000 units/mL) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis and blepharoconjunctivitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus viridan; Haemophilus influenzae; Pseudomonas aeruginosa*.

*Efficacy for this organism in this organ system was studied in fewer than 10 infections.

This medication has a broad FDA approval for "surface ocular bacterial infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "surface ocular bacterial infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Mild to moderate surface ocular bacterial infections:

  • Instill 1 drop in the affected eye(s) every 3 hours (maximum of 6 doses per day) for a period of 7 – 10 days.

 

►Recurrent corneal erosion:

  • Follow normal dosing patterns.

How Supplied:  
  • 10  mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59˚ – 77˚F (15˚ – 25˚C).
  • Protect from light.


TROPICAMIDE (tropicamide (0.5%; 1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegics
Indications/Usage:

Indicated for mydriasis and cycloplegia for diagnostic procedures.


Typical Dosing:  

Refraction: 

  • Instill 1 or 2 drops of 1% solution in the eye(s), repeated in 5 minutes. If patient is not seen within 20 – 30 minutes, an additional drop may be instilled to prolong mydriatic effect.
  • Individuals with heavily pigmented irides may require higher strength or more doses.
  • Mydriasis will reverse spontaneously with time, typically in 4 – 8 hours. However, in some cases, complete recovery may take up to 24 hours.

Examination of fundus: 

  • For examination of fundus, instill 1 or 2 drops of 0.5% solution 15 – 20 minutes prior to examination.
  • Individuals with heavily pigmented irides may require higher strength or more doses.
  • Mydriasis will reverse spontaneously with time, typically in 4 – 8 hours. However, in some cases, complete recovery may take up to 24 hours.

How Supplied:  
  • 0.5% ophthalmic solution
    • 15 mL bottles
  • 1% ophthalmic solution 
    • 2 mL bottles
    • 3 mL bottles
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Do not refrigerate or store at high temperatures.
  • Keep container tightly closed.


TRUSOPT (dorzolamide hydrochloride (2%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Carbonic Anhydrase Inhibitors
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma:

  • InstIll 1 drop in the affected eye(s) 3 times daily.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 10 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 86°F (15° – 30°C).
  • Protect from light.


Assistance: Payment Assistance

TYLENOL EXTRA STRENGTH (acetaminophen (500 mg) tablets; (500 mg) capsules)
Over the Counter
Oral
Capsules
Tablets
Acetaminophen
Indications/Usage:

Temporarily relieves minor aches and pains and temporarily reduces fever.


Typical Dosing:  

Minor aches and pains or fever:

  • Do not take more than directed (see overdose warning in package insert).
  • Adults and children  12 years of age:
    • Take 2 tablets or capsules every 6 hours while symptoms last.
    • Do not take > 6 tablets or capsules in 24 hours, unless directed by a doctor.
    • Do not use for > 10 days unless directed by a doctor.
  • Children < 12 years:
    • Ask a doctor.

How Supplied:  
  • 500 mg capsules
  • 500 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store between 68° – 77°F (20° – 25°C).


231 items found